A5025409152- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
- T-cell and B-cell Immunology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Xenotransplantation and immune response
- Dietary Effects on Health
- Liver physiology and pathology
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
Nanjing Medical University
2012-2025
Jiangsu Cancer Hospital
2024-2025
Abstract Background and Aim The study aims to investigate the efficacy safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib immune checkpoint inhibitors (ICIs) versus ICIs for hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) refractoriness. Methods Patients intermediate or advanced TACE‐refractory HCC who received without HAIC between 2020 2022 were retrospectively reviewed. tumor response, overall survival (OS), progression‐free (PFS),...
The combination of regorafenib and immune checkpoint inhibitor (ICI) has been the most popular second-line systemic therapy for advanced hepatocellular carcinoma (HCC). However, considering good anti-tumor performance lenvatinib, combined immunotherapy on basis lenvatinib after first-line failure is also in clinical practice. This study aimed to compare efficacy safety plus ICI (TACE-R-I) versus (TACE-L-I) patients with HCC failure. In this single-center retrospective study, 164 were...
Liver transplantation is an established therapy for end-stage liver diseases. Graft rejection occurs unless the recipient receives immunosuppression after transplantation. This study aimed to explore mechanism of acute allografts in rats pre-treated with total body irradiation eliminate passenger lymphocytes and define role CD4+CD25+ regulatory T cells induction immunotolerance recipient. Male Lewis were used as donors male DA recipients. Rats randomly assigned following four groups: control...
e16243 Background: HCC is a common malignant tumor worldwide, safer and more potent treatments are desperately needed to increase the survival rates of patients. Some studies have shown that transcatheter arterial chemoembolization/hepatic infusion chemotherapy (TACE/HAIC) combined with systemic therapies shows potential synergistic effects in patients HCC, ZGDH3-III RCT's findings showed donafenib(D) highly safe effective as first-line treatment for uHCC. This study aimed evaluate efficacy...
The response to transarterial chemoembolization (TACE) varies among individuals with hepatocellular carcinoma (HCC). This study aimed identify a biomarker for predicting TACE in HCC patients and investigate its correlations the tumor microenvironment pre-TACE radiomics features.